Alpha Teknova Inc. Common Stock (TKNO)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn good returns on capital and trade at a discount to intrinsic value. Alpha Teknova does not yet meet that test. It produces critical reagents for therapies, vaccines, and molecular diagnostics. Revenue has grown from $36.7M in fiscal 2023 (year ended 2023-12-31) to $37.7M in fiscal 2024 (year ended 2024-12-31) to $40.5M in fiscal 2025 (year ended 2025-12-31), but net losses remain severe: -$36.8M, -$26.7M, and -$17.3M, respectively. The trend is improving, and in fiscal Q2 2026 (quarter ended 2026-06-30) revenue was $12.2M with a $3.2M net loss, versus $10.3M revenue and a $3.6M net loss in fiscal Q2 2025 (quarter ended 2025-06-30). Still, trailing free cash flow is -$7.4M, so the company consumes cash. FairStock calculations show ROE of -24.19% and ROCE of -9.28%, confirming weak returns. The balance sheet has modest leverage - D/E 0.44 - and Altman Z 6.19, but Piotroski is 4/9. At the 2026-10-13 close of $8.22, FairStock calculates P/B 7.03 and a negative P/E of -26.52; with a -1.7% FCF yield, there is no earnings-based bargain. The Lynch category is none because it lost money in each of the last four years. I see a small, specialized reagent supplier, but no durable moat proven by profits. The market is already valuing it for a turnaround. Until it earns consistent profits and generates cash, I cannot call this a Graham-style value investment.

In plain English: Alpha Teknova makes special chemicals and lab supplies used to develop therapies, vaccines, and medical tests. The company is selling more than it did a few years ago, but it still loses money and uses cash. Compared with the net assets shown in its books, the stock looks expensive, so the price depends on a future turnaround that has not happened yet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer